Cancers related to viral agents that have a direct role in carcinogenesis: Pathological and diagnostic techniques

Journal of Clinical Pathology

Volumn 65, Issue 8, 2012, Pages 680-686

  Carbone, Antonino ^a   De Paoli, Paolo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

AIDS PATIENT; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANUS CARCINOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; EPSTEIN BARR VIRUS; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LARGE CELL LYMPHOMA; MOUTH CARCINOMA; NASOPHARYNX CARCINOMA; NK T CELL LYMPHOMA; NONHUMAN; OROPHARYNX CARCINOMA; PENIS CARCINOMA; POLYMERASE CHAIN REACTION; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; REVIEW; TONSIL CARCINOMA; UTERINE CERVIX CARCINOMA; VAGINA CARCINOMA; VIREMIA; VULVA CARCINOMA;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HUMANS; NEOPLASMS; ONCOGENIC VIRUSES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TUMOR VIRUS INFECTIONS; VIREMIA; VIROLOGY;

EID: 84864563321     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200717     Document Type: Review

References (82)

1. World Cancer Report. In: Boyle P, Levin B, eds. World Health Organization, International Agency for Research on Cancer. World Health Organization - International Agency for Research on Cancer, Lyon, France, 2008.
2. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens. Part B: biological agents. Lancet Oncol 2009;10:321-2.
3. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-68. (Pubitemid 39331148)
4. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-92. (Pubitemid 30646489)
5. Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol Mech Dis 2006;1:375-404.
6. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004;10:803-21. (Pubitemid 38198878)
7. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003:22:5108-21. (Pubitemid 37059592)
8. World Health Organization classification of tumours. Pathology and genetics. In: Barnes L, Eveson JW, Reichart P, et al, eds. Head & Neck Tumours. Lyon: IARC Press, 2005.
9. IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans, Volume 70 (1997), Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8. Lyon, France, 1997.
10. Sousa H, Pinto-Correia AL, Medeiros R, et al. Epstein-Barr virus is associated with gastric carcinoma: the question is what is the significance? World J Gastroenterol 2008;14:4347-51.
11. Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008;13:577-85. (Pubitemid 351872874)
12. Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009;113:1213-24.
13. Carbone A, Tirelli U, Gloghini A, et al. Human immunodeficiency virus associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J Clin Oncol 1993;11:1674-81.
14. Hamilton-Dutoit SJ, Rea D, Raphael M, et al. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 1993;143:1072-85. (Pubitemid 24070550)
15. Klein E, Kis LL, Klein G. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 2007;26:1297-305. (Pubitemid 46328467)
16. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006;108:3786-91. (Pubitemid 44864560)
17. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol 2007;60:1365-72. (Pubitemid 350247252)
18. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian cooperative group on AIDS and tumors. J Clin Oncol 1995;13:1758-67.
19. Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus-associated Hodgkin's disease derives from post-germinal center B cells. Blood 1999;93:2319-26. (Pubitemid 29153635)
20. Schulz TF. The pleiotropic effects of Kaposi's sarcoma herpesvirus. J Pathol 2006;208:187-98. (Pubitemid 43126112)
21. Hengge UR, Ruzicka T, Tyring SK, et al. Update on kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2002;2:344-52. (Pubitemid 34595974)
22. Kalt I, Masa SR, Sarid R. Linking the Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to human malignancies. Methods Mol Biol 2009;471:387-407.
23. Pak F, Pyakural P, Kokhaei P, et al. HHV-8/KSHV during the development of kaposi's sarcoma: evaluation by polymerase chain reaction and immunohistochemistry. J Cutan Pathol 2005;32:21-7. (Pubitemid 40174101)
24. Stürzl M, Konrad A, Alkharsah KR, et al. The contribution of systems biology and reverse genetics to the understanding of Kaposi's sarcoma-associated herpesvirus pathogenesis in endothelial cells. Thromb Haemost 2009;102:1117-34.
25. Godfrey A, Anderson J, Papanastasiou A, et al. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 2005;105:2510-18. (Pubitemid 40387053)
26. Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 2004;199:993-1003. (Pubitemid 38481090)
27. Wies E, Mori Y, Hahn A, et al. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 2008;111:320-7.
28. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-9.
29. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50. (Pubitemid 37328947)
30. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110:525-41. (Pubitemid 43736116)
31. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010;10:550-60.
32. Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006;16:83-97.
33. Gillespie MB, Rubinchik S, Hoel B, et al. Human papillomavirus and oropharyngeal cancer: what you need to know in 2009. Curr Treat Options Oncol 2009;10:296-307.
34. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19. (Pubitemid 29406813)
35. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009;15:6758-62.
36. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004;324:17-27. (Pubitemid 38737395)
37. IARC. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007;90:1-636.
38. IARC. Monograph on the Evaluation of Carcionogenic Risks to Humans. vol. 64. WHO, Lyon, France, 1995.
39. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(Suppl 10):K1-16.
40. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32. (Pubitemid 46986496)
41. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500-10.
42. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-54. (Pubitemid 44162407)
43. Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007;99:962-72. (Pubitemid 47073502)
44. Schulz TF. Cancer and viral infections in immunocompromised individuals. Int J Cancer 2009;125:1755-63.
45. Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 2008;10:279-92. (Pubitemid 352022708)
46. Li C, Chen RS, Hung SK, et al. Detection of Epstein-Barr virus infection and gene expression in human tumors by microarray analysis. J Virol Methods 2006;133:158-66.
47. De Paoli P, Pratesi C, Bortolin MT. The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers. J Cancer Res Clin Oncol 2007;133:809-15. (Pubitemid 350218917)
48. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010;23:350-66.
49. Lo YM, Leung SF, Chan LY, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 2000;60:2351-5. (Pubitemid 30262420)
50. Gulley ML. Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn 2001;3:1-10. (Pubitemid 32266144)
51. Yen CY, Lu MC, Tzeng CC, et al. Detection of EBV infection and gene expression in oral cancer from patients in Taiwan by microarray analysis. J Biomed Biotechnol 2009;2009:904589.
52. Tsai DE, Douglas L, Andreadis C, et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transpl 2008;8:1016-24. (Pubitemid 351537762)
53. Gärtner B, Preiksaitis JK. EBV viral load detection in clinical virology. J Clin Virol 2010;48:82-90.
54. To EW, Chan KC, Leung SF, et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 2003;9:3254-9. (Pubitemid 37082718)
55. Shotelersuk K, Khorprasert C, Sakdikul S, et al. Epstein-Barr virus DNA in serum/ plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res 2000;6:1046-51. (Pubitemid 30159366)
56. Leung SF, Tam JS, Chan AT, et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 2004;50:339-45. (Pubitemid 38156375)
57. Bortolin MT, Pratesi C, Dolcetti R, et al. Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Lett 2006;233:247-54. (Pubitemid 43327380)
58. Tong JH, Tsang RK, Lo KW, et al. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. Clin Cancer Res 2002;8:2612-19. (Pubitemid 34856348)
59. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006;24:5414-18. (Pubitemid 46623174)
60. Leung SF, Chan AT, Zee B, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003;98:288-91. (Pubitemid 36828452)
61. Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer 1999;84:442-8. (Pubitemid 29337135)
62. Gandhi MK, Lambley E, Burrows J, et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive hodgkin's lymphoma. Clin Cancer Res 2006;12:460-4. (Pubitemid 43166136)
63. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005;56:155-67. (Pubitemid 41278654)
64. Fan SQ, Ma J, Zhou J, et al. Differential expression of Epstein-Barr virus-encoded RNA and several tumor-related genes in various types of nasopharyngeal epithelial lesions and nasopharyngeal carcinoma using tissue microarray analysis. Hum Pathol 2006;37:593-605.
65. Van Baarle D, Wolthers KC, Hovenkamp E, et al. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDSrelated non-hodgkin lymphoma. J Infect Dis 2002;186:405-9. (Pubitemid 34816324)
66. Carbone A, Gloghini A, Vaccher E, et al. Kaposi's sarcoma-associated herpesvirus/ human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J Mol Diagn 2005;7:17-27. (Pubitemid 40310161)
67. Tedeschi R, Marus A, Bidoli E, et al. Human herpesvirus 8 DNA quantification in matched plasma and PBMCs samples of patients with HHV8-related lymphoproliferative diseases. J Clin Virol 2008;43:255-9.
68. Engels EA, Biggar RJ, Marshall VA, et al. Detection and quantification of kaposi's sarcoma-associated herpesvirus to predict AIDS-associated kaposi's sarcoma. AIDS 2003;17:1847-51. (Pubitemid 37000104)
69. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to kaposi's sarcoma. Lancet 1995;346:799-802.
70. Pellet C, Kerob D, Dupuy A, et al. Kaposi's sarcoma-associated herpesvirus viremia is associated with the progression of classic and endemic kaposi's sarcoma. J Invest Dermatol 2006;126:621-7. (Pubitemid 43255651)
71. Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 2008;9:336-88. (Pubitemid 352015641)
72. Quinlivan EB, Zhang C, Stewart PW, et al. Elevated virus loads of kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J Infect Dis 2002;185:1736-44. (Pubitemid 34615467)
73. Simonelli C, Tedeschi R, Gloghini A, et al. Prognostic factors in human herpesvirus 8-related lymphoproliferative disorders associated with HIV infection. J Clin Oncol 2006;24:209-10.
74. Bourboulia D, Aldam D, Lagos D, et al. Short- and long-term effects of highly active antiretroviral therapy on kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 2004;18:485-93. (Pubitemid 38365876)
75. Sullivan RJ, Pantanowitz L, Casper C, et al. HIV/AIDS: epidemiology, pathophysiology, and treatment of kaposi sarcoma-associated herpesvirus disease: kaposi sarcoma, primary effusion lymphoma, and multicentric castleman disease. Clin Infect Dis 2008;47:1209-15.
76. Oksenhendler E. HIV-associated multicentric castleman disease. Curr Opin HIV AIDS 2009;4:16-21.
77. Braakhuis BJ, Brakenhoff RH, Meijer CJ, et al. Human papilloma virus in head and neck cancer: the need for a standardised assay to assess the full clinical importance. Eur J Cancer 2009;45:2935-9.
78. Zaravinos A, Mammas IN, Sourvinos G, et al. Molecular detection methods of human papillomavirus (HPV). Int J Biol Markers 2009;24:215-22.
79. Briolat J, Dalstein V, Saunier M, et al. HPV prevalence, viral load and physical state of HPV-16 in cervical smears of patients with different grades of CIN. Int J Cancer 2007;121:2198-204. (Pubitemid 47585598)
80. Klaes R, Woerner SM, Ridder R, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 1999;59:6132-6. (Pubitemid 30035633)
81. Cox JT. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J Clin Virol 2009;45(Suppl 1): S3-12. Erratum in: J Clin Virol 2010;47:299.
82. Conway C, Chalkley R, High A, et al. Next-generation sequencing for simultaneous determination of HPV load, subtype, and associated genomic copy number changes in tumors. J Mol Diagn. Published Online First: 9 January 2012. PMID: 22240447